---
title: "Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292787294.md"
description: "Evercore ISI analyst Amit Daryanani maintains a Hold rating on Elevance Health (ELV), citing solid fundamentals offset by regulatory and cost pressures. While core operations are strong, risks like medical inflation limit upside. RBC Capital also holds ELV with a $439 price target. Additionally, TipRanks launched the NYSE:RANK ETF tracking its US Momentum Analysts Index."
datetime: "2026-07-15T14:55:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292787294.md)
  - [en](https://longbridge.com/en/news/292787294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292787294.md)
generator: "portal-rs"
---

# Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health

Evercore ISI analyst Amit Daryanani has maintained their neutral stance on ELV stock, giving a Hold rating on July 9.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Amit Daryanani has given his Hold rating due to a combination of factors related to Elevance Health’s current positioning and outlook. He views the company’s core health insurance and managed care operations as fundamentally solid, supported by stable membership trends and disciplined underwriting, but believes much of this strength is already reflected in the share price, limiting near‑term upside.

At the same time, Daryanani sees a mixed risk‑reward profile as regulatory uncertainties, medical cost inflation, and reimbursement dynamics could constrain margin expansion and earnings visibility. While he acknowledges Elevance’s strategic initiatives in care management and diversified services, he concludes that the balance between potential catalysts and execution or policy risks is best captured by a neutral stance, warranting a Hold rather than a more aggressive recommendation.

In another report released on July 9, RBC Capital also maintained a Hold rating on the stock with a $439.00 price target.

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)

## Related News & Research

- [Vista Investment Management Makes New $2.14 Million Investment in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/296699815.md)
- [TrinityBridge Ltd Acquires New Position in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/296605778.md)
- [1 Trade to Make Now as Inflation Fears Swirl in September](https://longbridge.com/en/news/297798498.md)
- [Jefferies Financial Group Inc. Purchases 34,972 Shares of Elevance Health, Inc. $ELV](https://longbridge.com/en/news/297303474.md)
- [Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening | GH Stock News](https://longbridge.com/en/news/297650116.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**